Selection of antiepileptic drugs: a practical approach

Mayo Clinic Proceedings

Volumn 71, Issue 8, 1996, Pages 778-786

  Britton, Jeffrey W ^a   So, Elson L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ACETYLSALICYLIC ACID; ALCOHOL; ANTIINFECTIVE AGENT; CARBAMAZEPINE; CHLORAMPHENICOL; CIMETIDINE; CONTRACEPTIVE AGENT; CYCLOSERINE; DEXAMETHASONE; DOXYCYCLINE; ETHOSUXIMIDE; FELBAMATE; FOLIC ACID; FUROSEMIDE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; METHADONE; PETHIDINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; QUINIDINE; STEROID; THEOPHYLLINE; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; WARFARIN;

ABSENCE; DRUG INTERACTION; EPILEPSY; FOCAL EPILEPSY; GRAND MAL EPILEPSY; HUMAN; METABOLISM; MYOCLONUS EPILEPSY; REVIEW; ANTICONVULSANT THERAPY; BEHAVIOR DISORDER; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; SEDATION; SEIZURE, EPILEPSY AND CONVULSION; SEXUAL DYSFUNCTION; TREATMENT PLANNING; VERTIGO;

ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSIES, MYOCLONIC; EPILEPSIES, PARTIAL; EPILEPSY; EPILEPSY, ABSENCE; EPILEPSY, TONIC-CLONIC; HUMANS;

EID: 0030211122     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/71.8.778     Document Type: Article

References (76)

1. Hauser WA, Hesdorffer DC. Epilepsy: Frequency, Causes and Consequences. New York: Demos, 1990
2. Masland RL. Commission for the control of epilepsy. Neurology 1978; 28:861-863
3. Steiner TJ, Yuen AW. Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy [abstract]. Epilepsia 1994; 35(Suppl 8):31
4. Yuen AW and 106 investigators. Lamotrigine vs carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy [abstract]. Epilepsia 1994; 35(Suppl 8):31
5. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994; 35:795-801
6. Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1994; 28:11881196
7. Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32:157163
8. Penry JK, So EL. Refractoriness of absence seizures and phénobarbital [abstract]. Neurology 1981; 31(Suppl):158
9. Snead OC III, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985; 313:916921
10. Lorentz de Haas AM, Kuilman M. Ethosuximide (a-ethyl-amethylsuccinimide) and grand mal. Epilepsia 1964; 5:9096
11. Wilder BJ, Ramsay RE, Murphy J V, Karas BJ, Marquardt K, Hammond EJ. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983; 33:1474-1476
12. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35:359-367
13. Strumia S, Hirsch E, Moszkowski J, Marescaux C. Lamotrigine effect in typical absences [abstract]. Epilepsia 1994;35(Suppl8):118
14. Mikati MA, Holmes GL. Temporal lobe epilepsy. In: Wyllie E, editor. The Treatment of Epilepsy: Principles and Practice. Philadelphia: Lea & Febiger, 1993: 513-524
15. Mattson RH, Cramer JA, Collins JF, Smith DB, DelgadoEscueta AV, Browne TR, et al. Comparison of carbamazepine, phénobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985:313:145-151
16. Chadwick D, Turnbull DM. The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures. J Neurol Neurosurg Psychiatry 1985; 48:1073-1077
17. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48:639-644
18. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry 1982:45:55-59
19. Mattson RH, Cramer JA, Collins JF, Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonicclonic seizures in adults. N Engl J Med 1992; 327:765-771
20. Leiderman DB. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia 1994; 35(Suppl 5):S74-S76
21. Yuen AW. Lamotrigine: a review of antiepileptic efficacy. Epilepsia 1994; 35(Suppl 5):S33-S36
22. Leppik IE. Felbamate. Epilepsia 1995; 36(Suppl 2):S66-S72
23. Mosewich RK, So EL. A clinical approach to the classification of seizures and epileptic syndromes. Mayo Clin Proc 1996; 71:405-414
24. Mattson RH, Cramer JA. Crossover from polytherapy to monotherapy in primary generalized epilepsy. Am J Med 1988; 84:23-28
25. Serratosa JM, Delgado-Escueta AV. Generalized myoclonic seizures. In: Wyllie E, editor. The Treatment of Epilepsy: Principles and Practice. Philadelphia: Eea & Febiger, 1993: 411-424
26. Serratosa JM, Delgado-Escueta AV. Juvenile myoclonic epilepsy. In: Wyllie E, editor. The Treatment of Epilepsy: Principles and Practice. Philadelphia: Lea & Febiger, 1993: 552-570
27. Eadie MJ, Tyrer JH. Anticonvulsant Therapy: Pharmacological Basis and Practice. 3rd ed. Edinburgh: Churchill Livingstone, 1989
28. Janz D, Christe W. Generalized epilepsies. In: Resor SR Jr, Kutt H, editors. The Medical Treatment of Epilepsy. New York: Marcel Dekker, 1992: 145-162
29. Janz D. Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta Neurol Scand 1985; 72:449-459
30. Genton P, Roger J. The progressive myoclonus epilepsies. In: Wyllie E, editor. The Treatment of Epilepsy: Principles and Practice. Philadelphia: Lea & Febiger, 1993: 571-583
31. Asconapé J, Diedrich A, DellaBadia J. Gabapentin-associated myoclonus [abstract]. Neurology 1995; 45(Suppl 4):A249-A250
32. Bachman DS. Use of valproic acid in treatment of infantile spasms. Arch Neurol 1982; 39:49-52
33. Snead OC III, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology 1983; 33:966970
34. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991; 6(Suppl 2):S52S59
35. Vies JS, van der Heyden AM, Ghijs A, Troost J. Vigabatrin in the treatment of infantile spasms. Neuropediatrics 1993: 24:230-231
36. RichensA. Safety of lamotrigine. Epilepsia 1994; 35(Suppl 5):S37-S40
37. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989:39:201-207
38. Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann Neurol 1982; 11:309-312
39. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379-385
40. Vining EP, Mellitis ED, Dorsen MM, Cataldo MF, Quaskey SA, Spielberg SP, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phénobarbital and valproic acid. Pediatrics 1987; 80:165-174
41. Schmidt D. Connective tissue disorders induced by antiepileptic drugs. In: Oxley J. Janz D, Meinardi H, editors. Chronic Toxicity of Antiepileptic Drugs. New York: Raven Press, 1983: 1 15-124
42. Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O'Brien LA, et al. Risk factors for falls as a cause of hip fractures in women. N Engl J Med 1991 ; 324:1326-1331
43. Soelberg Sorenson P, Hammer M. Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. Eur J Clin Pharmacol 1984; 26:719-722
44. Beermann B, Edhag O. Depressive effects of carbamazepine on idioventricular rhythm in man. BMJ 1978; 2:171-172
45. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. JAMA 1983; 249:762-765
46. So EL, Penry JK. Adverse effects of phenytoin on peripheral nerves and neuromuscular junctions. Epilepsia 1981; 22:467-473
47. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329:1383-1388
48. Painter MJ, Pippenger C, Wasterlain C, Barmada M, Pitlick W, Carter G, et al. Phénobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. Neurology 1981;31:1107-1112
49. Terrence C, Alberts M. Phenytoin dosage in ambulant epileptic patients. J Neurol Neurosurg Psychiatry 1978; 41:463465
50. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994;44(Suppl5):S17-S22
51. Krauss GL, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology 1995; 45:594-595
52. Hunt PA, Wu-Chen ML, Handal NJ, Chang CT, Gomez M, Howell TR, et al. Bone disease induced by anticonvulsant therapy and treatment with calcitriol (1,25-dihydroxyvitamin D3). Am J Dis Child 1986; 140:715-718
53. Brodie MJ, Forrest G, Rapeport WG. Carbamazepine 10,11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br J Clin Pharmacol 1983; 16:747-749
54. Levy RH, Moreland TA, Morselli PL, Guyot M, BrachetLiermain A, Loiseau P. Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia 1984; 25:338345
55. Kondo T, Kaneko S, Otani K, Ishida M, Hirano T, Fukushima Y, et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia 1992;33:172-177
56. Stephens JR, Levy RH. Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. Pharmaceutisch Weekblad [Sei Ed] 1992; 14(3A):118-121
57. Kochen W, Schneider A, Ritz A. Abnormal metabolism of valproic acid in fatal hepatic failure. Eur J Pediatr 1983; 141:30-35
58. So EL, Ruggles KH, Cascino GD, Ahmann PA, Weatherford KW. Seizure exacerbation and status epilepticus related to carbamazepine-10,ll-epoxide. Ann Neurol 1994; 35:743746
59. Wilder BJ, Bruni J. Seizure Disorders: Pharmacological Approach to Treatment. New York: Raven Press, 1981: 3539
60. Jonkman JH, Upton RA. Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984; 9:309-334
61. Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M. Phenytoin-dexamethasone: a possible drugdrug interaction [letter]. JAMA 1985; 254:2062-2063
62. Hansen JM, Siersbaek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971 ; 12:539-543
63. Nappi JM. Warfarin and phenytoin interaction [letter]. Ann Intern Med 1979; 90:852
64. Panegyres PK, Rischbieth RH. Fatal phenytoin warfarin interaction [letter]. Postgrad Med J 1991; 67:98
65. Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20:519525
66. Crawford P, Chadwick D, Cleland P, Tjia J, Cowie A, Back DJ, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986; 33:23-29
67. Shenfield GM. Oral contraceptives: are drug interactions of clinical significance? Drug Saf 1993; 9:21-37
68. Wilder BJ, Willmore LJ, Bruni J, Villarreal HJ. Valproic acid: interaction with other anticonvulsant drugs. Neurology 1978; 28:892-896
69. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25:433-443
70. Brennan RW, Dehejia H, Kutt H, Verebely K, McDowell F. Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. Neurology 1970; 20:687-693
71. Kutt H. Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia 1984; 25(Suppl 2):S118S131
72. Darley J. Interaction between phenytoin and fluoxetine. Seizure 1994; 3:151-152
73. Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. BMJ 1982; 285:261262
74. Kater RM, Roggin G, Tobon F, Zieve P, Iber FL. Increased rate of clearance of drugs from the circulation of alcoholics. Am J Med Sei 1969; 258:35-39
75. Kutt H, Haynes J, Verebely K, McDowell F. The effect of phénobarbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes. Neurology 1969; 19:611-616
76. Gunderson CH. The impact of new pharmaceutical agents on the cost of neurologic care. Neurology 1995; 45:569-572